CDT

S-1 - CDT Equity Inc. (0001896212) (Filer)

8-K - CDT Equity Inc. (0001896212) (Filer)

4 - CDT Equity Inc. (0001896212) (Issuer)

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept. 02, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company") today announced that, following the recent issuance of shares and the exercise of pre-funded warrants, the Company had 13,693,866 shares of Common Stock issued and outstanding as of August 31, 2026. Based on the closing price of CDT’s Common Stock on August 31, 2026, the Company had a market capitalisation of approximately $23.0 million. CDT’s stockholders’ equity, as reported in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, was approximately $103 million. Following the recent issuances and related corporate actions, CDT also confirm

8-K - CDT Equity Inc. (0001896212) (Filer)

8-K - CDT Equity Inc. (0001896212) (Filer)

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept. 01, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company") today announced the appointment of James Bligh, co-founder of Conduit Pharmaceuticals Limited (now CDT), as Chief Executive Officer. Mr. Bligh brings extensive public-markets, corporate finance and transaction experience to the role and will lead the Company as it enters its next phase of growth and value creation. Dr. Andrew Regan has been appointed as CEO of Sarborg Limited. Mr. Bligh co-founded Conduit Pharmaceuticals Limited in 2019 and has played an important role in the development and evolution of the business. Prior to Conduit, he spent more than a d

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Aug. 28, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today announced that new solid forms and alternative crystal structures of its existing drug compounds, show enhanced physical property advantages, including improved stability, solubility, manufacturability, over existing forms of these compounds. These solid forms are patent-protected under the Company’s Substance of Matter IP and could support new formulations tailored to specific patient needs, prospectively increasing the commercial life of the underlying assets. Following implementation of Sarborg’s Signature Intelligence to identify new potential uses

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Aug. 25, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today announced that it has entered into a SAFE note with Pep'd Inc. ("Pep'd"), a US-based peptide company, expanding CDT's exposure to the growing US peptide market (the "Transaction"). Upon Pep’d closing an Equity Financing, this SAFE will automatically convert into a number of shares of Safe Preferred Stock, depending on the Pep’d Capitalization at that time and a Valuation Cap of $10,000,000. The Transaction extends CDT's strategy of identifying and backing high-potential and science-driven assets, and reflects the Company's growing interest in AI-enable

8-K/A - CDT Equity Inc. (0001896212) (Filer)

8-K/A - CDT Equity Inc. (0001896212) (Filer)

10-Q - CDT Equity Inc. (0001896212) (Filer)

DEFA14A - CDT Equity Inc. (0001896212) (Filer)

DEF 14A - CDT Equity Inc. (0001896212) (Filer)

8-K - CDT Equity Inc. (0001896212) (Filer)

8-K/A - CDT Equity Inc. (0001896212) (Filer)

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Aug. 03, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company") today announced that it has entered into a strategic transaction to increase its equity stake in Sarborg Limited ("Sarborg"), an agentic AI signature intelligence business operating across multiple industrial sectors, to 22.7% through the issuance of pre-funded warrants to purchase up to 12,131,770 shares of the Company’s common stock, subject to shareholder approval at the Company’s annual meeting of stockholders on August 28, 2026 (the "Transaction"). The Transaction increases the Company’s shareholding in Sarborg, which was initially acquired in February 2

PRE 14A - CDT Equity Inc. (0001896212) (Filer)

8-K - CDT Equity Inc. (0001896212) (Filer)

8-K - CDT Equity Inc. (0001896212) (Filer)

NAPLES, Fla. and CAMBRIDGE, United Kingdom, July 20, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today notes the announcement from Sarborg Limited regarding the filing of a new patent application covering a large set of field-deployable, two-component combination interventions for sugarcane cultivation, generated through Sarborg's quantum-enabled PRISM platform. According to Sarborg, the filing organizes its claimed combinations around six distinct application configurations, each defined by the growth stage of application, the delivery route, the dose and timing, and the agronomic target addressed. Within this framework, Sarborg has identified 606 fiel

8-K - CDT Equity Inc. (0001896212) (Filer)

NAPLES, Fla. and CAMBRIDGE, United Kingdom, July 16, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), announces that its board of directors has approved a 1-for-10 reverse stock split of the Company’s common stock, to ensure continued compliance with the Nasdaq bid-price rule. The Company’s stockholders approved future reverse stock splits, their timing, and granted the board of directors authority to determine future exact split ratios. The reverse stock split will become effective on July 17, 2026, at 5:00 pm, Eastern Time (the "Effective Time"), and the Company’s common stock is expected to begin trading on a reverse stock split-adjusted basis on The Nasd

10-Q - CDT Equity Inc. (0001896212) (Filer)

8-K - CDT Equity Inc. (0001896212) (Filer)